Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis

Grandgirard, Denis; Loeffler, Jutta M.; Fischetti, Vincent A.; Leib, Stephen L. (2008). Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. Journal of infectious diseases, 197(11), pp. 1519-1522. Cary, N.C.: The University of Chicago Press 10.1086/587942

	Text __nas-ifik.unibe.ch_ifik_Forschung_Gr_Leib_SHARED GROUP FOLDER_own papers_Phage Lytic Enzyme Cpl-1 for.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (903kB) | Request a copy
Preview	Text 197-11-1519.pdf - Other Available under License Publisher holds Copyright. Download (902kB) | Preview

Treatment of bacterial meningitis caused by Streptococcus pneumoniae is increasingly difficult, because of emerging resistance to antibiotics. Recombinant Cpl-1, a phage lysin specific for S. pneumoniae, was evaluated for antimicrobial therapy in experimental pneumococcal meningitis using infant Wistar rats. A single intracisternal injection (20 mg/kg) of Cpl-1 resulted in a rapid (within 30 min) decrease in pneumococci in cerebrospinal fluid (CSF) by 3 orders of magnitude lasting for 2 h. Intraperitoneal administration of Cpl-1 (200 mg/kg) led to an antibacterial effect in CSF of 2 orders of magnitude for 3 h. Cpl-1 may hold promise as an alternative treatment option in pneumococcal meningitis.

Interest & Impact

Downloads

121 since deposited on 04 Oct 2013
19 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item